Setrobuvir - ANA598

StephenW

              US patent for Anadys Pharma covering setrobuvir            
              PBR Staff Writer              Published 02 June 2011                              The US Patent and Trademark Office has granted Patent No 7,939,524 to Anadys Pharmaceuticals’ setrobuvir (ANA598), a Direct-Acting Antiviral (DAA) in development for chronic hepatitis C virus infection (HCV).
               The patent recognizes the company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds.
Setrobuvir, which has received fast track status from the US Food and Drug Administration, is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.
It has a well-characterized safety database in which more than 150 subjects have received the agent to date.
In the ongoing Phase IIb study, setrobuvir is being tested in combination with Pegasys and Copegus in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.
The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.
Anadys expects to receive antiviral response data through 12 weeks for all patients, including the 8 week time point used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.
Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.

StephenW

美国专利Anadys制药覆盖setrobuvir
预算审查人员作家出版2011年6月2日

美国专利和商标局授予专利号为7939524至Anadys制药公司的setrobuvir（ANA598），直接动抗病毒药（的DAA）在慢性丙型肝炎病毒感染（HCV）的发展。

专利认识到公司的知识份子的物质和对setrobuvir使用方法和相关化合物组成的财产权利。

Setrobuvir，已获得美国食品和药物管理局的快速跟踪状态，是丙型肝炎病毒RNA聚合酶抑制剂，属于化学类被称为非核苷。

它有一个良好的安全数据库的特点，其中150多个科目已收到代理的日期。

在正在进行的IIb阶段的研究中，setrobuvir正在测试用PEGASYS和Copegus组合两个治疗初治患者和患者谁失败，干扰素和利巴韦林治疗前的过程。

这项研究的主要终点是持续病毒学应答的病人24周后完整的治疗，如SVR24称。

Anadys预计将收到通过12周的抗病毒反应的数据对所有病人，包括8周的时间点为响应引导治疗初治患者的治疗中使用的2011年第三季度。

经过24周的抗病毒反应的数据，预计在2011年第四季度。